These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 26892970)

  • 1. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases.
    Arsenault BJ; Perrot N; Puri R
    Clin Pharmacol Ther; 2018 Aug; 104(2):257-268. PubMed ID: 29737015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Hovland A; Retterstøl K; Mollnes TE; Halvorsen B; Aukrust P; Lappegård KT
    Scand Cardiovasc J; 2020 Oct; 54(5):274-279. PubMed ID: 32500743
    [No Abstract]   [Full Text] [Related]  

  • 8. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid pharmacotherapy for treatment of atherosclerosis.
    Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
    Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.
    Tuñón J; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Hoefer IE; Ketelhuth DFJ; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Bäck M
    Cardiovasc Res; 2019 Jan; 115(1):10-19. PubMed ID: 30534957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.
    Kohli P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):199-210. PubMed ID: 23580658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.
    Vincent J
    Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.
    Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB
    J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
    Mason RP; Libby P; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk.
    Mukherjee D; Nissen SE
    Curr Vasc Pharmacol; 2024; 22(3):171-179. PubMed ID: 38141196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.